Tumor Biology
From 1st January 2021, Tumor Biology will be published by IOS Press. This site is no longer accepting submissions, please submit your manuscript via https://www.editorialmanager.com/tub/
For further information about IOS Press and Author Instructions please see https://www.iospress.nl/journal/tumor-biology/#submission-of-manuscript or contact editorial@iospress.nl.
Tumor Biology is a peer-reviewed, open access journal, which focusses on experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Please see the Aims and Scopes tab for further information.
This journal is published on behalf of the International Society for Oncology and Biomarkers (ISOBM).
This journal is a member of the Committee on Publication Ethics (COPE).
For information on the journal’s indexing and metrics please click here.
Why publish in Tumor Biology?
- Indexed by PubMed: MEDLINE
- Rapid but rigorous peer review, and quick decision times
- Open access dissemination of your article
- Authors retain copyright under a Creative Commons license
Open access article processing charge (APC) information
The APC for this journal is currently $1500 USD.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.
From 1st January 2021, Tumor Biology will be published by IOS Press. This site is no longer accepting submissions, please submit your manuscript via https://www.editorialmanager.com/tub/
For further information about IOS Press and Author Instructions please see https://www.iospress.nl/journal/tumor-biology/#submission-of-manuscript or contact editorial@iospress.nl.
Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression.is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. covers all aspects oftumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression.
Specific topics of interest include, but are not limited to:
- Pathway analyses,
- Non-coding RNAs,
- Circulating tumor cells,
- Liquid biopsies,
- Exosomes,
- Epigenetics,
- Cancer stem cells,
- Tumor immunology and immunotherapy,
- Tumor microenvironment,
- Targeted therapies,
- Therapy resistance
- Cancer genetics,
- Cancer risk screening.
Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines.
The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication.
Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).
| Magdalena Chechlinska, PhD, Dr Habil | Maria Sklodowska-Curie National Research Institute of Oncology, Poland |
| Changyan Chen | Northeastern University, USA |
| Stefan Holdenrieder | University of Bonn, Germany |
| Magdalena Kowalewska | Maria Sklodowska-Curie National Research Institute of Oncology, Poland |
| Salvatore Piscuoglio | University Hospital Basel, Switzerland |
| Luca Quagliata | Universitätsspital Basel, Switzerland |
| Marta Sanchez-Carbayo | University of the Basque Country, Spain |
| Vivian Barak | Hadassah Medical Center, Israel |
| Javier Castresana | University of Navarra, Spain |
| Caroline Chapman | University of Nottingham, UK |
| Chi Hin Cho | The Chinese University of Hong Kong, Hong Kong, China |
| Jose Luis Costa | University of Porto, Portugal |
| Elefterious Diamandis | Mount Sinai Hospital, Canada |
| Joe Duffy | UCD Dublin, Ireland |
| Sten Hammarström | Umeå Universitet, Sweden |
| Kohzoh Imai | The University of Tokyo, Japan |
| Chien-Feng (Angelo) Li | Chi Mei Medical Center, Taiwan |
| Leendert H. J. Looijenga | Erasmus MC Cancer Institute, Rotterdam, The Netherlands |
| Andrea Nicolini | University of Pisa, Italy |
| Barbara Pedley | University College London, UK |
| Johanna (Hanny) M.A. Pijnenborg | Radboud University Medical Center, The Netherlands |
| Ulf Hakan Stenman | University of Helsinki, Finland |
| Iwona Wlodarska | KU Leuven, Leuven, Belgium |
From 1st January 2021, Tumor Biology will be published by IOS Press. This site is no longer accepting submissions, please submit your manuscript via https://www.editorialmanager.com/tub/
For further information about IOS Press and Author Instructions please see https://www.iospress.nl/journal/tumor-biology/#submission-of-manuscript or contact editorial@iospress.nl.